Message #10 From:
Stock News Bot Date: August 23, 2005 02:00:00 AM
GTHA News GeneThera, Inc. Aligns with Emerging Equity Group, Inc. to Expand International Presence among Investor Community
WHEAT RIDGE, Colo.--(BUSINESS WIRE)--Aug. 23, 2005--GeneThera, Inc. (OTCBB:GTHA), a molecular biotechnology company focused on the detection and treatment of disease in animals using state-of-the-art technology, is pleased to announce its new relationship with Emerging Equity Group, Inc. (EEG). EEG is a full-service advisory firm that combines technology, strategic alliances, and critical insight to serve private and public organizations worldwide, as well as individual and institutional investors.
EEG's analysts compare companies from different perspectives including special focus on how they stack up vertically in their own market. They are intensely attentive to differences among business strategies in an industry segment. As a result, they offer their clients exceptional perspective on comparative values in competitive environments.
Dr. Antonio Milici, CEO of GeneThera, Inc., commented: "We are excited for the opportunity to work alongside an internationally respected company like Emerging Equity Group. We feel that it is very important to continue expanding the audience for GeneThera's live animal test worldwide and EEG is the perfect fit."
Mark Daniels, Director of the Private Client Group of Emerging Equity Group, Inc., added: "We hold our investment considerations to the highest standard. That is why Emerging Equity Group prefers to work with businesses on the verge of a dramatic growth cycle. We feel GeneThera and its ability to detect disease in animals with a live blood test will be very well received in the international investment community."
About GeneThera
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colo. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the healthcare industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Chronic Wasting Disease, a disease affecting elk and deer in North America, and Mad Cow Disease affecting cattle worldwide. Future plans include all infectious disease potentially affecting domesticated livestock as well as wildlife intended for human consumption, with particular priority being given to Johne's disease in cattle.
About Emerging Equity Group
Emerging Equity Group's strategic investment banking, brokerage, and contractual alliances provide clients with access to global registered brokerage networks, venture capital corporations, and large market institutions.
Emerging Equity Group is a full-service advisory firm that provides a complete set of investment services, including:
-- Onshore and offshore portfolio management
-- Investment banking
-- Retail brokerage
-- Corporate finance
-- Arbitrage
-- Online trading
-- Private client services
"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
